Published in Cell on January 20, 2012
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell (2016) 2.32
Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol (2014) 2.21
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol (2012) 1.57
Toward understanding and exploiting tumor heterogeneity. Nat Med (2015) 1.51
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res (2012) 1.47
ADAM8 as a drug target in pancreatic cancer. Nat Commun (2015) 1.46
Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell (2012) 1.40
Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification. PLoS One (2016) 1.38
Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A (2013) 1.26
Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25
Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci U S A (2012) 1.25
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol (2013) 1.24
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol (2013) 1.22
Ductal pancreatic adenocarcinoma. Dtsch Arztebl Int (2014) 1.14
Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11
Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther (2012) 1.10
Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol (2013) 1.08
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One (2014) 1.05
Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol (2012) 1.04
Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci U S A (2014) 1.03
Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv (2014) 1.03
Cancer Systems Biology: a peek into the future of patient care? Nat Rev Clin Oncol (2014) 1.01
The mathematics of cancer: integrating quantitative models. Nat Rev Cancer (2015) 1.00
2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford) (2013) 0.99
CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One (2014) 0.99
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol (2015) 0.96
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther (2013) 0.95
Reconstructing metastatic seeding patterns of human cancers. Nat Commun (2017) 0.92
Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images. PLoS One (2013) 0.91
Pancreatic cancer surgery: past, present, and future. Chin J Cancer Res (2015) 0.89
Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma. Mol Cancer (2014) 0.89
Cell-to-cell variability in cell death: can systems biology help us make sense of it all? Cell Death Dis (2014) 0.87
Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics (2013) 0.87
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol (2015) 0.87
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2013) 0.86
Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget (2015) 0.86
Laparoscopic pancreatic surgery for benign and malignant disease. Nat Rev Gastroenterol Hepatol (2016) 0.86
Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) (2012) 0.85
Patient specific tumor growth prediction using multimodal images. Med Image Anal (2014) 0.85
Pancreatic cancer metastasis: are we being pre-EMTed? Curr Pharm Des (2015) 0.85
Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med (2015) 0.84
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer (2016) 0.84
New challenges in perioperative management of pancreatic cancer. World J Gastroenterol (2015) 0.84
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Sci Rep (2016) 0.83
Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. Cancer Res (2015) 0.83
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. J Radiat Oncol (2013) 0.83
A new method to estimate parameters of the growth model for metastatic tumours. Theor Biol Med Model (2013) 0.82
Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med (2013) 0.82
Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Cancer Res (2015) 0.82
Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials. Med Hypotheses (2015) 0.82
Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model. Theor Biol Med Model (2014) 0.82
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget (2015) 0.81
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Dis Model Mech (2015) 0.81
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol (2013) 0.81
Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell (2015) 0.81
Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. World J Gastroenterol (2012) 0.80
The value of monitoring to control evolving populations. Proc Natl Acad Sci U S A (2015) 0.80
Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. World J Gastroenterol (2015) 0.80
Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. Curr Opin Gastroenterol (2012) 0.80
Emerging role of the KRAS-PDK1 axis in pancreatic cancer. World J Gastroenterol (2014) 0.80
Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill. PLoS Comput Biol (2016) 0.79
Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput Biol (2013) 0.79
Accelerating cancer systems biology research through Semantic Web technology. Wiley Interdiscip Rev Syst Biol Med (2012) 0.79
Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton. J Extracell Vesicles (2017) 0.78
External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy. HPB (Oxford) (2015) 0.77
Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors (2015) 0.77
Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford) (2013) 0.77
The evolution of tumor metastasis during clonal expansion with alterations in metastasis driver genes. Sci Rep (2015) 0.77
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. Trends Endocrinol Metab (2016) 0.76
Optimal reaction coordinate as a biomarker for the dynamics of recovery from kidney transplant. PLoS Comput Biol (2014) 0.76
Computational Modelling of Metastasis Development in Renal Cell Carcinoma. PLoS Comput Biol (2015) 0.76
Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.76
Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer (2016) 0.75
ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca(2+)/RhoA pathway. Cell Death Dis (2017) 0.75
Navigating uncharted territory. Nat Rev Cancer (2012) 0.75
Prediction of postoperative liver regeneration from clinical information using a data-led mathematical model. Sci Rep (2016) 0.75
Long range personalized cancer treatment strategies incorporating evolutionary dynamics. Biol Direct (2016) 0.75
Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head? HPB (Oxford) (2013) 0.75
Early versus delayed initiation of adjuvant treatment for pancreatic cancer. PLoS One (2017) 0.75
RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. Mol Cell Oncol (2015) 0.75
Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. BMC Surg (2015) 0.75
The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future? J Gastrointest Oncol (2017) 0.75
Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol (2014) 0.75
Polymer nanoassemblies with solvato- and halo-fluorochromism for drug release monitoring and metastasis imaging. Ther Deliv (2015) 0.75
CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget (2016) 0.75
Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. World J Surg (2016) 0.75
Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol (2017) 0.75
Evolutionary dynamics and significance of multiple subclonal mutations in cancer. DNA Repair (Amst) (2017) 0.75
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int J Mol Sci (2017) 0.75
EMT and Treatment Resistance in Pancreatic Cancer. Cancers (Basel) (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Genetic instabilities in human cancers. Nature (1998) 22.76
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Pancreatic cancer. N Engl J Med (2010) 13.88
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Genetic instability in colorectal cancers. Nature (1997) 12.51
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
A phosphatase associated with metastasis of colorectal cancer. Science (2001) 3.86
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther (2005) 3.28
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res (2000) 2.58
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol (1995) 1.90
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79
Retracted Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev (2009) 1.74
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 1.57
Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle (2006) 1.54
Mutation rate of normal and malignant human lymphocytes. Cancer Res (1987) 1.42
Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer (2010) 1.41
Invasion emerges from cancer cell adaptation to competitive microenvironments: quantitative predictions from multiscale mathematical models. Semin Cancer Biol (2008) 1.29
The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg (2006) 1.20
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
Stochastic dynamics of metastasis formation. J Theor Biol (2005) 1.07
Unknown primary tumors metastatic to liver. J Clin Oncol (1998) 1.06
Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys (2010) 1.02
Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation. J Math Biol (2010) 1.00
Mathematical modeling of cell adhesion in shear flow: application to targeted drug delivery in inflammation and cancer metastasis. Curr Pharm Des (2007) 0.94
The evolution of tumor metastases during clonal expansion. J Theor Biol (2009) 0.93
The emergence of tumor metastases. Cancer Biol Ther (2007) 0.93
Mathematical Oncology: How Are the Mathematical and Physical Sciences Contributing to the War on Breast Cancer? Curr Breast Cancer Rep (2010) 0.88
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys (2009) 0.87
Predictive mathematical modeling in metastasis. Methods Mol Med (2001) 0.80
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther (2005) 3.28
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science (2005) 2.72
Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med (2003) 2.62
DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol (2011) 2.62
Synergy and discounting of cooperation in social dilemmas. J Theor Biol (2005) 2.49
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Stochastic tunnels in evolutionary dynamics. Genetics (2004) 2.42
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg (2005) 2.38
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Evolution of resistance during clonal expansion. Genetics (2006) 2.36
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab (2005) 2.30
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg (2007) 2.23
Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg (2012) 2.23
Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg (2013) 2.22
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol (2004) 2.22
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med (2009) 2.16
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol (2009) 2.10
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol (2003) 2.04
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg (2006) 2.03
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol (2015) 2.00
Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol (2008) 1.97
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res (2014) 1.96
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2007) 1.94
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res (2003) 1.90
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res (2006) 1.89
Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol (2002) 1.88
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol (2007) 1.84
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res (2008) 1.82
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78
Successful therapy must eradicate cancer stem cells. Stem Cells (2006) 1.78
Evolutionary dynamics of invasion and escape. J Theor Biol (2004) 1.78
Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol (2013) 1.76
Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther (2004) 1.74
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res (2008) 1.74
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol (2012) 1.71
Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types. Cancer Biol Ther (2007) 1.69
Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann Surg Oncol (2011) 1.69
Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg (2009) 1.68
The linear process of somatic evolution. Proc Natl Acad Sci U S A (2003) 1.66
Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg (2003) 1.66
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Close distal margin and rectal cancer recurrence after sphincter-preserving rectal resection. Dis Colon Rectum (2010) 1.64
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol (2007) 1.64
Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg (2005) 1.64